Genomics in Cancer Care

Global Genomics in Cancer Care Market to Reach US$28.5 Billion by 2032

The global market for Genomics in Cancer Care estimated at US$10.3 Billion in the year 2025, is expected to reach US$28.5 Billion by 2032, growing at a CAGR of 15.6% over the analysis period 2025-2032. Instruments, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth in the Consumables segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 20.7% CAGR

The Genomics in Cancer Care market in the U.S. is estimated at US$3.2 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2032 trailing a CAGR of 20.7% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.4% and 14.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.

Global Genomics in Cancer Care Market - Key Trends and Drivers Summarized

How Is Genomics Revolutionizing Cancer Care?

Genomics is transforming cancer care by enabling a more personalized and precise approach to treatment. By analyzing the genetic makeup of cancer cells, clinicians can identify specific mutations and biomarkers that drive tumor growth, allowing for targeted therapies that are tailored to an individual’s genetic profile. This personalized medicine approach has proven particularly effective in treating cancers such as breast, lung, and colon cancer, where traditional therapies may have been less successful. Genomics not only enhances the accuracy of diagnosis but also helps predict how a patient will respond to specific treatments, reducing the need for trial-and-error approaches. As genetic testing becomes more affordable and accessible, genomics is becoming an integral part of cancer care, leading to more effective and less invasive treatment options.

What Are the Major Applications and Segments of Genomics in Cancer Care?

Key technologies include next-generation sequencing (NGS), microarray analysis, and polymerase chain reaction (PCR), each offering different capabilities in genetic testing and analysis. In terms of application, genomics is used for diagnostics, targeted therapies, and monitoring recurrence or treatment resistance. NGS is rapidly becoming the gold standard for comprehensive genomic profiling, enabling the identification of multiple mutations in a single test. The market is also segmented by end-users, with hospitals, cancer research institutes, and pharmaceutical companies being the primary adopters. Regionally, North America leads the market due to high healthcare spending and advanced cancer research infrastructure, while Asia-Pacific is emerging as a growth region, driven by increasing cancer prevalence and expanding healthcare access.

How Are Technological Advances Driving Genomics in Cancer Care?

Technological advancements in genomics are revolutionizing cancer care by enhancing the accuracy, speed, and affordability of genetic testing. The advent of next-generation sequencing (NGS) has made it possible to sequence entire genomes quickly and cost-effectively, providing clinicians with comprehensive data on cancer mutations and biomarkers. In addition, advances in bioinformatics and AI are enabling the rapid analysis of vast genomic datasets, improving diagnostic accuracy and facilitating the discovery of new therapeutic targets. Liquid biopsies, a non-invasive method of analyzing tumor DNA from blood samples, are also gaining traction, allowing for continuous monitoring of cancer progression and treatment response. These innovations are making personalized cancer care more accessible and effective, pushing the boundaries of what’s possible in oncology.

What Factors Are Driving the Growth in the Genomics in Cancer Care Market?

The growth in the genomics in cancer care market is driven by several factors, including the increasing prevalence of cancer, the rising demand for personalized medicine, and advancements in genetic testing technologies. Next-generation sequencing and other advanced diagnostic tools are enabling faster and more accurate identification of cancer-related mutations, fueling the adoption of genomics in clinical settings. The growing focus on targeted therapies, which are designed to attack specific genetic mutations, is also driving the demand for genomics-based cancer treatment. Government initiatives and research funding aimed at advancing cancer genomics are further propelling market growth, while the expansion of genetic testing into emerging markets is creating new opportunities for industry players.

SCOPE OF STUDY:

The report analyzes the Genomics in Cancer Care market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Instruments, Consumables, Services); Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction & Purification, Other Technologies); End-Use (Research Institutes, Hospitals, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Affymetrix
• Agilent Technologies
• BGI
• Bio-Rad Laboratories
• Cancer Genetics Inc
• GE Healthcare
• Illumina Inc
• Life technologies
• Myriad Genetics
• Pacific Biosciences
• Perkin Elmer
• Qiagen
• Quest Diagnostics
• Roche Diagnostics
• Sigma Aldrich

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more